Genome-wide association studies with patients suffering from CMC have identified additional polymorphisms that cause defects in the IL-17 response [2], clearly indicating that the IL-17 pathway plays a non-redundant role in antifungal immunity. The gene discussed is IL17A; the disease is Chronic mucocutaneous candidosis.